The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1430
Vortioxetine (Brintellix/Trintellix) for Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 5/10/16: In May 2016, the brand name of vortioxetine was changed from Brintellix to Trintellix.

The FDA has approved vortioxetine (vor" tye ox' e teen; Brintellix/Trintellix – Takeda/Lundbeck), a new serotonergic drug, for treatment of major depressive disorder. Like vilazodone (Viibryd)1, another serotonergic antidepressant, it has been claimed to have a low incidence of sexual side effects and no significant effect on weight.

MECHANISM OF ACTION — Vortioxetine has multiple effects on serotonin neurotransmission. It selectively inhibits reuptake of serotonin and acts as an agonist or antagonist at various serotonin receptors. The clinical significance of these activities, other than serotonin reuptake inhibition, have not been established, but the manufacturer describes vortioxetine as a multimodal antidepressant.

CLINICAL STUDIES — Three unpublished 8-week trials (summarized in the package insert) found vortioxetine 20 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Vortioxetine (Brintellix/Trintellix) for Depression
Article code: 1430b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian